Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Oppenheimer has reduced its price target on Artivion Inc. (NYSE:AORT) to $40.00 from $42.00 while maintaining an Outperform rating on the cardiac implant manufacturer. The stock, currently trading at $32.70 with a market capitalization of $1.54 billion, is approaching its 52-week high of $33.39. According to InvestingPro analysis, the company appears overvalued at current levels.
The adjustment follows Artivion’s second-quarter 2025 revenue report of $113 million, representing 14% year-over-year growth on a pro forma, constant currency basis. This performance exceeded both Oppenheimer’s and consensus estimates of $109 million and $108 million, respectively. The company maintains strong financial health with a current ratio of 5.53 and an impressive gross profit margin of 63.94%.
Artivion’s aortic stents and grafts segment grew 22%, while its On-X product line increased 24%, driven by cross-selling initiatives and new data. The company reported that a cybersecurity incident from the fourth quarter of 2024 had a $1.7 million impact on second-quarter results, with the remaining tissue backlog expected to clear by the end of the third quarter.
The company recently received FDA IDE approval to begin its Arcevo-LSA pivotal trial, with enrollment expected to commence before year-end. Artivion has raised its full-year 2025 revenue guidance to $435-443 million from the previous $423-435 million range, compared to Oppenheimer’s estimate of $430 million and consensus of $427 million.
Management expressed confidence in maintaining double-digit top-line growth while expanding the bottom line at twice that rate, with AMDS and NEXUS products potentially driving further growth, assuming current timelines remain intact. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report for deeper analysis of Artivion’s growth prospects and valuation metrics.
In other recent news, Artivion Inc. has reported impressive financial results for the second quarter of 2025. The company achieved a significant earnings per share (EPS) turnaround, posting an EPS of $0.24, which far exceeded the forecasted loss of $0.0033. Artivion’s revenue reached $113 million, marking a 14% increase year-over-year, surpassing both Oppenheimer’s and consensus estimates of $109 million and $108 million, respectively. Following these strong results, Oppenheimer raised its price target for Artivion to $40.00 from $32.00, while maintaining an Outperform rating. These developments reflect positively on the company’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.